^
Association details:
| Biomarker: | MET N375S |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4918 - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism
Published date:
09/30/2019
Excerpt:
METN375S was associated with significantly shorter relapse-free survival (RFS) in SCC of the head and neck (HNSCC; P = 0.005) and lung (LUSC; P = 0.029)....Two patients with refractory HNSCC who completed 1 cycle of afatinib, a pan-HER inhibitor, showed radiological tumour shrinkage and reduction in metabolic activity, with partial response by RECIST 1.1 measurement observed in one patient.
DOI:
10.1093/annonc/mdz268
Trial ID:
